Company Overview of AbCellera Biologics Inc.
AbCellera Biologics Inc. offers development of antibody therapeutics to improve patient outcomes. It offers microfluidic single cell analysis including cell culture, protein analysis, and single cell genomics. It has a strategic alliance with Teva Pharmaceutical Industries Limited. The company was founded in 2012 and is based in Vancouver, Canada.
2125 East Mall
Vancouver, BC V6T 1Z4
Founded in 2012
Key Executives for AbCellera Biologics Inc.
President, Chief Executive Officer, and Director
Compensation as of Fiscal Year 2016.
AbCellera Biologics Inc. Key Developments
Abcellera Biologics Enters into Research Agreement with Teva Pharma
Jun 15 17
AbCellera Biologics Inc. entered into a research agreement with Teva Pharmaceutical Industries Ltd., a pharmaceutical company, to apply AbCellera Biologics proprietary monoclonal antibody (mAb) screening platform for the discovery of antibodies that modulate the function of an undisclosed membrane protein target elected by Teva Pharma. Under the terms of the agreement, AbCellera Biologics will receive an upfront payment and research support, as well as milestone and royalty payments based on Teva Pharma development and commercialization of antibodies generated under the agreement. Earlier on February 2, 2016, Teva Pharma entered into a research agreement with AbCellera Biologics to apply AbCellera Biologics single cell antibody platform for the discovery of rare monoclonal antibodies. This agreement enables AbCellera Biologics and Teva Pharma to generate lead antibody candidates against membrane targets using AbCellera Biologics antibody discovery platform.
AbCellera Biologics Inc. Enters into Collaborative Research Effort with Sanofi Pasteur
Jun 6 17
AbCellera Biologics Inc. has entered into a collaborative research effort with Sanofi Pasteur. The project will use AbCellera's single-cell screening platform to profile vaccine-specific human antibodies elicited by seasonal influenza vaccination and to generate large panels of human monoclonal antibodies with desired binding profiles to various influenza strains. Seasonal influenza affects millions of people every year, and results in 250,000 to 500,000 deaths annually. Although vaccination provides protection when matched to the circulating strains, there is a place for new and improved vaccines when the circulating viruses do not match. Understanding the critical determinants that drive broad and protective human immune responses will guide the research and development of next-generation influenza vaccines. AbCellera's microfluidic platform combines screening speed and throughput with unique capabilities for selecting antibodies with defined properties using a wide array of single-cell assays. This platform allows for in-depth screening of immune cells from human blood samples, and the rapid discovery and sequencing of large numbers of human monoclonal antibodies with desired binding properties across multiple antigens. The ability to rapidly annotate antibody sequences with functional data opens a new and important tool for vaccine research.
AbCellera Announces Multi-Target Research Collaboration with Pfizer
Jan 5 17
AbCellera Biologics Inc. announced a new therapeutic antibody discovery collaboration with Pfizer Inc. AbCellera will apply its proprietary monoclonal antibody (mAb) screening platform to attempt to discover function-modulating antibodies against undisclosed membrane protein targets. Under the terms of the agreement, AbCellera will receive an upfront payment and research support, and will be eligible to receive up to approximately $90 million in contingent milestone payments, as well as tiered mid-to-low single digit royalty payments based on Pfizer's development and commercialization of antibodies that may be generated under this collaboration. Further terms of the agreement are not disclosed.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries